Hussein S, Abdelazem A, Abdelmoneem S, Abdelnabi A, Khamis T, Obaya A
Asian Pac J Cancer Prev. 2022; 23(8):2735-2742.
PMID: 36037128
PMC: 9741902.
DOI: 10.31557/APJCP.2022.23.8.2735.
Xu Y, Chai B, Wang X, Wu Z, Gu Z, Liu X
J Cancer. 2022; 13(7):2352-2361.
PMID: 35517408
PMC: 9066207.
DOI: 10.7150/jca.67990.
Dehghan F, Boozarpour S, Torabizadeh Z, Alijanpour S
Onco Targets Ther. 2019; 12:5601-5607.
PMID: 31371997
PMC: 6628966.
DOI: 10.2147/OTT.S199508.
Orellana E, Li C, Lisevick A, Kasinski A
Cell Cycle. 2019; 18(15):1798-1811.
PMID: 31258013
PMC: 6649554.
DOI: 10.1080/15384101.2019.1634956.
Gunaratne P, Pan Y, Rao A, Lin C, Hernandez-Herrera A, Liang K
Cancer. 2019; 125(14):2409-2422.
PMID: 31012964
PMC: 6617807.
DOI: 10.1002/cncr.32053.
MicroRNA-384 inhibits proliferation migration and invasion of glioma by targeting at CDC42.
Gu G, Wang L, Zhang J, Wang H, Tan T, Zhang G
Onco Targets Ther. 2018; 11:4075-4085.
PMID: 30038507
PMC: 6052920.
DOI: 10.2147/OTT.S166747.
miR-130a and miR-145 reprogram Gr-1CD11b myeloid cells and inhibit tumor metastasis through improved host immunity.
Ishii H, Vodnala S, Achyut B, So J, Hollander M, Greten T
Nat Commun. 2018; 9(1):2611.
PMID: 29973593
PMC: 6031699.
DOI: 10.1038/s41467-018-05023-9.
Dysregulation of miRNA and its potential therapeutic application in schizophrenia.
Cao T, Zhen X
CNS Neurosci Ther. 2018; 24(7):586-597.
PMID: 29529357
PMC: 6490029.
DOI: 10.1111/cns.12840.
Noncoding RNA in drug resistant sarcoma.
Li X, Shen J, Hornicek F, Xiao T, Duan Z
Oncotarget. 2017; 8(40):69086-69104.
PMID: 28978183
PMC: 5620323.
DOI: 10.18632/oncotarget.19029.
Identifying the miRNA signature associated with survival time in patients with lung adenocarcinoma using miRNA expression profiles.
Yerukala Sathipati S, Ho S
Sci Rep. 2017; 7(1):7507.
PMID: 28790336
PMC: 5548864.
DOI: 10.1038/s41598-017-07739-y.
miRNA‑1271 inhibits cell proliferation in neuroglioma by targeting fibronectin 1.
Gong J, Wang Z, Liu Z
Mol Med Rep. 2017; 16(1):143-150.
PMID: 28535003
PMC: 5482146.
DOI: 10.3892/mmr.2017.6610.
Epigenetic Regulation of Telomere Maintenance for Therapeutic Interventions in Gliomas.
Naderlinger E, Holzmann K
Genes (Basel). 2017; 8(5).
PMID: 28513547
PMC: 5448019.
DOI: 10.3390/genes8050145.
Transcriptome profiling reveals miR-9-3p as a novel tumor suppressor in gastric cancer.
Meng Q, Xiang L, Fu J, Chu X, Wang C, Yan B
Oncotarget. 2017; 8(23):37321-37331.
PMID: 28418879
PMC: 5514911.
DOI: 10.18632/oncotarget.16310.
Decreased expression of miR-378 correlates with tumor invasiveness and poor prognosis of patients with glioma.
Li B, Wang Y, Li S, He H, Sun F, Wang C
Int J Clin Exp Pathol. 2015; 8(6):7016-21.
PMID: 26261592
PMC: 4525926.
MiRNA-based therapeutic intervention of cancer.
Naidu S, Magee P, Garofalo M
J Hematol Oncol. 2015; 8:68.
PMID: 26062952
PMC: 4465004.
DOI: 10.1186/s13045-015-0162-0.
MicroRNA-mediated regulation of KRAS in cancer.
Kim M, Slack F
J Hematol Oncol. 2014; 7:84.
PMID: 25433809
PMC: 4263212.
DOI: 10.1186/s13045-014-0084-2.
MicroRNAs in soft tissue sarcomas: overview of the accumulating evidence and importance as novel biomarkers.
Fujiwara T, Kunisada T, Takeda K, Uotani K, Yoshida A, Ochiya T
Biomed Res Int. 2014; 2014:592868.
PMID: 25165708
PMC: 4139009.
DOI: 10.1155/2014/592868.
miR-615-5p is epigenetically inactivated and functions as a tumor suppressor in pancreatic ductal adenocarcinoma.
Gao W, Gu Y, Li Z, Cai H, Peng Q, Tu M
Oncogene. 2014; 34(13):1629-40.
PMID: 24769899
DOI: 10.1038/onc.2014.101.
MicroRNAs networks in thyroid cancers: focus on miRNAs related to the fascin.
Samimi H, Zaki Dizaji M, Ghadami M, Shahzadeh Fazeli A, Khashayar P, Soleimani M
J Diabetes Metab Disord. 2013; 12(1):31.
PMID: 23815851
PMC: 7976609.
DOI: 10.1186/2251-6581-12-31.
Redundant miR-3077-5p and miR-705 mediate the shift of mesenchymal stem cell lineage commitment to adipocyte in osteoporosis bone marrow.
Liao L, Yang X, Su X, Hu C, Zhu X, Yang N
Cell Death Dis. 2013; 4:e600.
PMID: 23598412
PMC: 3641352.
DOI: 10.1038/cddis.2013.130.
